Despite the clinical success of photodynamic therapy (PDT), the application of this medical
technique is intrinsically limited by the low oxygen concentrations found in cancer tumors …

The efficacy of photodynamic therapy is typically reliant on the local concentration and
diffusion of oxygen. Due to the hypoxic microenvironment found in solid tumors, oxygen …

Protein inactivation by reactive oxygen species (ROS) such as singlet oxygen (1O2) and
superoxide radical (O2•–) is considered to trigger cell death pathways associated with …

Herein we present a series of DCA-Ir (III) co-drug complexes that preferentially accumulate
in mitochondria and selectively cause cancer cell metabolic alterations and were found to …

Iridium (III) complexes are potent candidates for photodynamic therapy (PDT), but some key
drawbacks still hamper clinical translation, such as poor operability in the phototherapeutic …

Among all molecules developed for anticancer therapies, photodynamic therapeutic agents
have a unique profile. Their maximal activity is specifically triggered in tumors by light, and …

Platinum-resistant cancer cells are sensitive to changes in the levels of reactive oxidative
species (ROS). Herein, we design a biotin-modified Ru (II) complex as a photosensitizer …

Clinical acceptance of photodynamic therapy is currently hindered by poor depth efficacy
and inefficient activation of the cell death machinery in cancer cells during treatment. To …

Conventional photodynamic therapy mainly causes a therapeutic effect on the primary tumor
through the localized generation of reactive oxygen species, while metastatic tumors remain …

We present a two-photon (2P, 800 nm) PDT cyclometalated Iridium (III) complex (Ir-Es) that
targets the intracellular nucleus. The complex is capable of migrating sequentially from the …